Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
|
|
- Berniece Maxwell
- 5 years ago
- Views:
Transcription
1 Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular Inst. Ochsner Clinical School-The UQ School of Medicine, New Orleans, LA
2 ATP III LDL-C and Non HDL-C Goals Risk Category CHD or equivalent (10-yr risk 20%) 2 risk factors (10-yr risk 20%) LDL-C (mg/dl) Non HDL-C (mg/dl) risk factors Adapted with permission from Expert Panel. Circulation. 2002;106:3143
3 2004 Lipid Guidelines CAD and risk equivalent-drug TX for LDL> 100 mg/dl CAD and risk equivalent-optional goal LDL< 70 mg/dl 2 or more risk factors-optional goal LDL <100 mg/dl In high risk patients,greater emphasis on drug combinations to treat HDL and TGs. Grundy SM et al. Circulation 2004;110:
4 New ACC/AHA 2013 Risk Assessment Guidelines Race-and Sex-Specific Pooled Cohort Equation to predict 10-year risk of first ASCVD in non- Hispanic AAs and Whites, years Derived from ARIC,CHS,Cardia,and Framingham original and offspring Age, gender, total and HDL-C,SBP, use of anti- HTN meds, DM, and current smoking Assess 30-yr or lifetime risk of ASCVD in yo without ASCVD or high short-term risk Goff DC et al. ACC/AHA Risk Assessment, JACC 2014;63:
5 New ACC/AHA 2013 Risk Assessment Guidelines-Risk in Ethnic Groups There is not sufficient data to assess risk in Hispanics, Asians, and Indians using these same data bases The current risk assessment will OVERESTIMATE risk in Hispanics and Asian populations The current risk assessment will UNDERESTIMATE risk in American Indians Goff DC et al. ACC/AHA Risk Assessment, JACC 2014;63:
6 New ACC/AHA 2013 Cholesterol Guidelines Emphasis on Clinical ASCVD ACS/MI Angina, stable or unstable Arterial Revascularization, coronary and other Stroke /TIA PAD, presumably atherosclerotic Stone NJ, et al. ACC/AHA Blood Cholesterol Guideline.JACC 2014;63:
7 New ACC/AHA 2013 Cholesterol Guidelines 4 Major Statin Benefit Groups ASCVD LDL-C 190 mg/dl and higher Diabetes, age year risk of major ASCVD of 7.5% and higher, age Stone NJ, et al. ACC/AHA Blood Cholesterol Guideline.JACC 2014;63:
8 New ACC/AHA 2013 Cholesterol Guidelines Keaney J. F. et al. NEJM, Nov
9 New ACC/AHA 2013 Cholesterol Guidelines Keaney J. F. et al. NEJM, Nov
10 New ACC/AHA 2013 Cholesterol Guidelines No Definitive Guidelines Age greater than 75 years w/o ASCVD or with LDL-C < 190 mg/dl DM ages Age w/o ASCVD and LDL-C < 190 mg/dl LDL-C and non-hdl-c goals Triglycerides, including Severe Non-Statin medications Stone NJ, et al. ACC/AHA Blood Cholesterol Guideline.JACC 2014;63:
11 New ACC/AHA 2013 Cholesterol Guidelines Special Issues in > 75 yrs No drug guidelines in those w/o ASCVD and with LDL-C < 190 mg/dl In general, use moderate dose as opposed to high-dose statins Fail to definitively treat many despite very high ASCVD risk Suggest discussing pros and cons of more vs less aggressive treatments Stone NJ, et al. ACC/AHA Blood Cholesterol Guideline.JACC 2014;63:
12 LDL-C Reduction Remains Fundamental to Major Cholesterol Treatment Guidelines and Recommendations Recommendations for Patients With Clinical ASCVD ASCVD = atherosclerotic cardiovascular disease; ACC = American College of Cardiology; AHA = American Heart Association; ADA = American Diabetes Association; NLA = National Lipid Association; AACE = American Association of Clinical Endocrinologists; IAS = International Atherosclerosis Society; ESC = European Society of Cardiology; EAS = European Atherosclerosis Society. *Percent LDL-C reduction defines treatment intensity and assesses adherence;1 also includes percent LDL-C reduction as an efficacy metric Stone NJ, et al. J Am Coll Cardiol. 2014;63: Keaney JF, et al. N Engl J Med. 2014;370: American Diabetes Association. Diabetes Care. 2015;38(suppl 1):S1-S Jacobson TA, et al. J Clin Lipidol. 2014;8: Jellinger PS, et al. Endocr Pract. 2012;18(suppl 1): Expert Dyslipidemia Panel, Grundy SM. J Clin Lipidol. 2013;7: Reiner Z, et al. Eur Heart J. 2011;32:
13 Percentage with CHD event Landmark Statin Trials: LDL-C Levels vs Events WOSCOPS-S WOSCOPS-P AFCAPS-S AFCAPS-P Primary prevention Pravastatin Lovastatin (90) 2.8 (110) 3.4 (130) 3.9 (150) 4.4 (170) 4.9 (190) LDL-C, mmol/l (mg/dl) 5.4 (210) S = statin treated; P = placebo treated Modified from Kastelein JJP. Atherosclerosis. 1999;143(suppl 1):S17-S21
14 Percentage with CHD event Landmark Statin Trials: LDL-C Levels vs Events WOSCOPS-S WOSCOPS-P AFCAPS-S ASCOT-S ASCOT-P AFCAPS-P Primary prevention Pravastatin Lovastatin Atorvastatin (90) 2.8 (110) 3.4 (130) 3.9 (150) 4.4 (170) 4.9 (190) 5.4 (210) LDL-C, mmol/l (mg/dl) S = statin treated; P = placebo treated Modified from Kastelein JJP. Atherosclerosis. 1999;143(suppl 1):S17-S21
15
16
17 REVERSAL Baseline Values Prava (n=249) Atorva (n=253) Age T Cholesterol LDL HDL Triglyceride CRP Nissen S. E., et. al., JAMA. 2004;291:
18 REVERSAL Follow-up Labs Prava (n=249) Atorva (n=253) P-Value mean % mean % TC <0.001 LDL <0.001 HDL =0.06 Trig <0.001 CRP <0.001 Nissen S. E., et. al., JAMA. 2004;291:
19 REVERSAL Change in Atheroma Nissen S. E., et. al., JAMA. 2004;291:
20 After ASTEROID CAMELOT plasebo REVERSAL pravastatin Change in Percent Atheroma Volume (%) REVERSAL atorvastatin A-Plus placebo ACTIVATE plasebo -0.6 ASTEROID rosuvastatin LDL-C
21 SATURN Trial A 2 year, randomized, double-blind, parallel group study comparing the effects of treatment with rosuvastatin 40 mg and atorvastatin 80mg on atherosclerotic disease burden as measured by IVUS in patients with CAD (n=1,300). Primary Outcome Measure: Comparison of the effects of rosuvastatin with atorvastatin on PAV, as measured by IVUS Nicholls SJ et al. NEJM;Nov 15,2011
22 SATURN Trial LDL lower on Rosuva vs Atorva( 62.6 vs 70.2; p< ) HDL higher on Rosuva vs Atorva( 50.4 vs 48.6; p= 0.01) Primary End-point-PAV( NS) Secondary End-point-TAV reduced slightly more with Rosuva vs Atorva( p=0.01) Nicholls SJ et al. NEJM; Nov 15,2011
23 TIMI 22: Study Design Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome <10 days and Total Cholesterol < 240 mg/dl ASA + Standard Medical Therapy Pravastatin 40 mg, qhs Atorvastatin 80 mg, qhs Gatifloxacin Placebo Gatifloxacin Placebo Duration: Mean 2 year follow-up (1001 events) Primary Endpoint: Death, MI, Documented UA requiring hospitalization, revascularization (> 30 days after randomization), or Stroke
24 TIMI 22 RESULTS: All-Cause Death or Major CV Events in All Randomized Subjects 30 Pravastatin 40mg 537/2063 (26.3%) % with Event Atorvastatin 80mg 464/2099 (22.4%) 16% RRR at 2 years (p = 0.005) Months of Follow-up Cannon, C, et al. NEJM 2004;35
25 Cumulative Rate of Recurrent MI or Death from Coronary Causes CRP Levels and Outcome after Statin Therapy 0.10 LDL cholesterol 70 mg/dl 0.10 CRP 2 (mg/l) LDL cholesterol < 70 mg/dl 0.04 CRP < 2 (mg/l) Follow-up (Years) Follow-up (Years) Ridker PM, et al. NEJM 2005;352:20-8
26 TNT: Design Screening: CHD patients LDL-C: mg/dL after washout Open-label Atorvastatin 10 mg/day Target LDL: <130mg/dL Randomized 10,000 men and women aged Atorvastatin 10mg/day Target LDL: 100mg/dL Atorvastatin 80mg/day Target LDL: 75mg/dL Objective: To assess whether reducing LDL-C aggressively to 75mg/dL will provide a greater reduction in CHD events than lowering LDL-C more moderately to 100mg/dL Primary Endpoint: Occurrence of major coronary event (i.e., CHD death or nonfatal MI) 5 year follow-up period and completion of study end of 2004
27 TNT: Baseline and final LDL cholesterol levels LDL cholesterol level Atorvastatin 10 (n=5006) Atorvastatin 80 (n=4995) Mean baseline LDL cholesterol levels (mg/dl) Final LDL cholesterol levels (mg/dl) LaRosa JC et al. N Engl J Med 2005;352:
28 TNT: Primary efficacy outcomes Outcome Total major cardiovascular events (%) Death from coronary heart disease (%) Atorvastatin 10 mg (n=5006) Atorvastatin 80 mg (n=4995) Hazard ratio (95% CI) ( ) ( ) Nonfatal MI (%) ( ) Resuscitation after cardiac arrest (%) Fatal or nonfatal stroke (%) ( ) ( ) p < LaRosa JC et al. N Engl J Med 2005;352:
29 JUPITER URANUS EARTH Will Jupiter Change the Course of Earth?
30 hscrp (mg/l) LDL (mg/dl) JUPITER Effects of rosuvastatin 20 mg on LDL, HDL, TG, and hscrp LDL decrease 50 percent at 12 months 10 0 HDL increase 4 percent at 12 months hscrp decrease 37 percent at 12 months Months TG (mg/dl) HDL (mg/dl) TG decrease 17 percent at 12 months Months Ridker et al NEJM 2008
31 JUPITER Primary Trial Endpoint : MI, Stroke, UA/Revascularization, CV Death Cumulative Incidence Number at Risk Rosuvastatin Placebo HR 0.56, 95% CI P < Number Needed to Treat (NNT 5 ) = Follow-up (years) Placebo 251 / % Rosuvastatin 142 / ,901 8,631 8,412 6,540 3,893 1,958 1, ,901 8,621 8,353 6,508 3,872 1,963 1, Ridker et al NEJM 2008
32 High Dose Atorvastatin After CVA/TIA(SPARCL Trial) 4731 pts after CVA/TIA with LDL mg/dl;80 mg atorva vs placeo 4.9 yrs;ldl 73 atorva,129 placebo Atorva reducedstroke16%(p=.03),cva/tia 2 3%(p<.001),major CAD 35%(P=.003),major CVD 20%(p=.002),and any CVD event 26%(p<.001) SPARCL;NEJM 2006;355:
33 Do Statins Cause Diabetes Statins increase the prevalence of T2DM(Sattar N et al;lancet 2010;375: ) High-dose or Intense statin therapy increases T2DM more so than lower doses(preiss D et al;jama 2011;304: ) Statins, more so higher dose or Intense doses, reduce clinical events in MetS and T2DM, as much or more so than in other patients.
34 Limitations of Statins Muscle Side Effects-consider Coenzyme Q 10 Many patients do not obtain all lipid goals despite intensive doses Considerable Residual Risk Concern about other Adverse Effects- Liver,Diabetes,Memory, etc Most effective in patients with higher CHD risk
35
36 Ezetimibe Therapy Implications of IMPROVE-IT Produces 15-20% reductions in LDL-C added to statins Negative results and publicity from ENHANCE IMPROVE-IT AHA Nov,2014 Over 18,000 post-acs;7 years;median LDL-C 69.9 to 53.2 md/dl Significant event reduction, absolute 2% and relative 6.4%;NNT 50 for 7 yr ( or 350 per year) DiNicolantonio J, Lavie CJ et al. Am J Med, on-line 2/27/15
37 10 PCSK9 Inhibitors Lowers LDL-C by Binding to PCSK9
38 PCSK9 Inhibition Indications ASCVD and Heterozygous FH in addition to maximally tolerated statin and nonpharmacologic therapy in those who need additional LDL-C Lowering Evolocumab also indicated for Homozygous FH
39 LDL Particles Are Cleared From the Plasma by Binding to LDL Receptors and Being Internalized by the Hepatocyte1-3 1 LDL binds to LDL receptor Intravascular LDL/LDL receptor 2 complex internalized by hepatocyte LDL degraded in 3 lysosome 4 LDL receptor recycled to cell surface Hepatocyte Recycled LDL receptors continue to clear plasma LDL 1. Brown MS, et al. Proc Natl Acad Sci U S A. 1979;76: Brown MS, et al. Science. 1986;232: Steinberg D, et al. Proc Natl Acad Sci U S A. 2009;106:
40 PCSK9 Binds to the LDL Receptor and Targets the LDL Receptor for Degradation1-3 Intravascular PCSK9: 1 made in hepatocyte, secreted 2 PCSK9 binds to LDL receptor 3 Internalization of entire complex 4 LDL receptor as part of entire complex is degraded 5 LDL receptor not recycled Hepatocyte Fewer LDL receptors on hepatocyte surface result in increased plasma LDL 1. Abifadel M, et al. Hum Mutat. 2009;30: Seidah NG, et al. Circ Res. 2014;114: Steinberg D, et al. Proc Natl Acad Sci U S A. 2009;106:
41 PCSK9 Inhibitors Binds to PCSK9, Preventing PCSK9 From Binding to the LDL Receptor1,2 Intravascular 1 PCSK9I binds to PCSK9 X 2 Inhibits PCSK9 from binding to LDL receptor 3 LDL receptor recycled, not degraded Hepatocyte LDL receptors can recycle to hepatocyte surface to clear more plasma LDL
42 ODYSSEY and LDL Cholesterol with Alirocumab Robinson JG et al, NEJM March 15, 2015
43 ODYSSEY and LDL-Cholesterol with Alirocumab Robinson JG et al. NEJM, March 15, 2015.
44 OSLER and LDL-Cholesterol with Evolocumab Sabatine MS et al. NEJM, March 15, 2015.
45 OSLER and LDL-Cholesterol with Evolocumab Sabatine MS et al. NEJM March 15, 2015
46 Nicholls, S. JAMA. doi: /jama
47 Evolucomab, LDL-C and Coronary Atheroma Progression Nicholls, S. JAMA. doi: /jama
48 Sabatine MS et al. NEJM 2017; 376:
49 Evolocumab and Major CVD Events Sabatine MS et al. NEJM 2017; 376:
50 Evolocumab and Major CVD Events Primary Efficacy End Point Sabatine MS et al. NEJM 2017; 376:
51 Evolocumab and Major CVD Events Key Secondary Efficacy End Point Sabatine MS et al. NEJM 2017; 376:
52 Evolocumab Reduced Risk of Composite CV Events by 20% in a Median of Only 2.2 Years 1,2 Evolocumab + statin (N=13,784)
53 Post-hoc exploratory analysis Risk Reduction with Evolocumab Changes Between Months 0-12 and Months Evolocumab + statin (N=13,784) Evolocumab + statin (N=13,784)
54 Efficacy of Evolocumab Was Generally Consistent Across Major Demographic and Disease Subgroups: Key Secondary Endpoint Favors Evolocumab Favors Evolocumab
55 Post-hoc analysis Patients With a More Recent MI Are at Higher Risk of a Subsequent Event Evolocumab Evolocumab
56 Bonaca MP et al. Circulation 2017:137:
57 Benefits of Evolocumab in PAD Bonaca MP et al. Circulation 2017:137:
58 Benefits of Evolocumab in PAD Bonaca MP et al. Circulation 2017:137:
59 Benefits of Evolocumab in PAD Bonaca MP et al. Circulation 2017:137:
60 Benefits of Evolocumab in PAD Bonaca MP et al. Circulation 2017:137:
61 Benefits of Evolocumab in PAD Bonaca MP et al. Circulation 2017:137:
62 Benefits of Evolocumab in PAD Bonaca MP et al. Circulation 2017:137:
63 Benefits of Evolocumab in PAD Bonaca MP et al. Circulation 2017:137:
64 EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS Investigators American College of Cardiology 66th Annual Scientific Session Late-Breaking Clinical Trial March 18, 2017
65 Cognition and Statins Case series and 2 small, 6-month RCTs with statins raised concern regarding cognitive deficits In 2012 FDA added risk of adverse cognitive effects to label of all statins However analyses from large scale RCTs do not support these findings and 2014 Statin Cognitive Safety Task Force* concluded that statins are not associated with cognitive side effects. *The National Lipid Task Force. Rojas-Fernandez CH, et al. J Clin.Lipidol. 2014;8(3 Suppl):S5-16.
66 Cognition and PCSK9 Inhibitors Brain synthesizes cholesterol locally mab (e.g., evolocumab) are too large to cross the intact bloodbrain barrier Nevertheless meta-analysis* of adverse events from 6 trials in 9581 pts suggested an increased risk with PCSK9 inhibitors: HR 2.3 [1.1, 4.9] Event rates low (<1%) Unadjudicated, diverse AE terms reported Not correlated with LDL-C achieved *Lipinski MJ, et al. Eur Heart J. 2016;37(6):
67 FOURIER: Summary Results FOURIER Study Population: 27,564 stable patients with CV disease, age years; additional CV risk factor(s), LDL 70 mg/dl (or non-hdl 100) Placebo SC Q2W or QM RANDOMIZED DOUBLE BLIND 26 mos. mean f/u Evolocumab SC 140 mg Q2W or 420 mg QM Evolocumab on background of statin c/w placebo: LDL-C by 59% CV outcomes on background of statin therapy Safe and well-tolerated Sabatine, MS et al. New Eng J Med 2017 (NEJMoa on-line)
68 EBBINGHAUS: Hypothesis The addition of evolocumab to statin therapy in patients with clinically evident vascular disease does not adversely affect cognitive function. Giugliano RP et al. Clin Card 2017;40:59 65
69 Secondary Endpoints
70 Secondary Endpoint Results
71 Cognitive Assessments by Nadir Achieved LDL-C and Treatment (Full Pop)
72 Investigator Reported Cognitive Adverse Events
73 Selecting Combination Therapy Statin Therapy LDL not at goal HDL not at goal TG not at goal Increase statin* Add niacin* Add fenofibrate* Add ezetimibe Add BAR PCSK9I Add niacin* Add fibrate* *Increased risk of myopathy Add niacin* Add fibrate* Add fish oils Grundy S. Am J Cardiol. 2002;90:1135
74 Summary and Conclusions The New Cholesterol Guidelines have many pros and cons These Guidelines have potential for over- and under-treatment The Guidelines emphasize evidence based therapy, especially with statins Statins have tremendous evidence in primary and especially secondary prevention The Guidelines may lead to under-treatment in the young elderly and in high-risk Combined Dyslipidemia and do not emphasize non-statin therapies (including Ezetimibe and PCSK9Is), but the latter 2 receive attention in recent updates.
75 Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular Inst. Ochsner Clinical School-The UQ School of Medicine, New Orleans, LA
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationEBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationEducational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationHyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine
Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine The new england journal of medicine Original Article Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationTHE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It? THE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It?
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA Lipidology and Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School and NYU Center for CV Prevention
More informationPCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy
PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for
More informationWorkshop. Todd Anderson MD / Jacques Genest MD
Workshop Todd Anderson MD / Jacques Genest MD Game-Changing Trials 2017 FOURIER Evolocumab n=27,564 HR 0.80 CANTOS Canakinumab n=10,061 HR 0.85 COMPASS Rivaroxaban + ASA n=27,395 HR 0.76 Key Secondary
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationLDL How Low can (should) you Go and be Safe
LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationWhats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i?
Whats new in lipid management, and Can your high CV risk patients benefit from a PCSK9i? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More information9/3/ AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis. Disclosure
2013 AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis Robert Gleeson MD Preven5ve Cardiology and Lipid Management Froedtert and The Medical College of Wisconsin Disclosure
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More information2/10/2016. Is it Time to Return to Cholesterol Goals for Optimal Patient Management? CON. Disclosures. Stipulations
Is it Time to Return to Cholesterol Goals for Optimal Patient Management? CON Donald M. Lloyd-Jones MD ScMFACC FAHA Eileen M. FoellProfessor Chair, Dept. of Preventive Medicine Senior Associate Dean Director,
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More information